Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale

Nature Reviews Cardiology, Published online: 05 April 2023; doi:10.1038/s41569-023-00872-4Factor XIa inhibitors are being tested in clinical trials, with the assumption that these agents are as effective as direct oral anticoagulants but cause fewer bleeding events. Findings from phase II trials of direct inhibitors of factor XIa for the prevention of first-ever and recurrent ischaemic stroke or recurrent major coronary artery events suggest fewer bleeding events but with uncertainty about efficacy.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research